Clinical trial
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
NCT00062114 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2004
- Completion date
- April 30, 2007
- Enrollment
- 84 (actual)
- Sites
- 94
Conditions
As the registry lists them; a condition with its own page is linked.